Nature Communications (Jan 2018)
Development of an oral once-weekly drug delivery system for HIV antiretroviral therapy
- Ameya R. Kirtane,
- Omar Abouzid,
- Daniel Minahan,
- Taylor Bensel,
- Alison L. Hill,
- Christian Selinger,
- Anna Bershteyn,
- Morgan Craig,
- Shirley S. Mo,
- Hormoz Mazdiyasni,
- Cody Cleveland,
- Jaimie Rogner,
- Young-Ah Lucy Lee,
- Lucas Booth,
- Farhad Javid,
- Sarah J. Wu,
- Tyler Grant,
- Andrew M. Bellinger,
- Boris Nikolic,
- Alison Hayward,
- Lowell Wood,
- Philip A. Eckhoff,
- Martin A. Nowak,
- Robert Langer,
- Giovanni Traverso
Affiliations
- Ameya R. Kirtane
- Department of Chemical Engineering and David H. Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology
- Omar Abouzid
- Department of Chemical Engineering and David H. Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology
- Daniel Minahan
- Department of Chemical Engineering and David H. Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology
- Taylor Bensel
- Department of Chemical Engineering and David H. Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology
- Alison L. Hill
- Program for Evolutionary Dynamics, Harvard University
- Christian Selinger
- Institute for Disease Modeling
- Anna Bershteyn
- Institute for Disease Modeling
- Morgan Craig
- Program for Evolutionary Dynamics, Harvard University
- Shirley S. Mo
- Program for Evolutionary Dynamics, Harvard University
- Hormoz Mazdiyasni
- Department of Chemical Engineering and David H. Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology
- Cody Cleveland
- Department of Chemical Engineering and David H. Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology
- Jaimie Rogner
- Department of Chemical Engineering and David H. Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology
- Young-Ah Lucy Lee
- Department of Chemical Engineering and David H. Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology
- Lucas Booth
- Department of Chemical Engineering and David H. Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology
- Farhad Javid
- Sarah J. Wu
- Department of Mechanical Engineering, Massachusetts Institute of Technology
- Tyler Grant
- Lyndra Inc
- Andrew M. Bellinger
- Lyndra Inc
- Boris Nikolic
- Biomatics Capital
- Alison Hayward
- Department of Chemical Engineering and David H. Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology
- Lowell Wood
- Institute for Disease Modeling
- Philip A. Eckhoff
- Institute for Disease Modeling
- Martin A. Nowak
- Program for Evolutionary Dynamics, Harvard University
- Robert Langer
- Department of Chemical Engineering and David H. Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology
- Giovanni Traverso
- Department of Chemical Engineering and David H. Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology
- DOI
- https://doi.org/10.1038/s41467-017-02294-6
- Journal volume & issue
-
Vol. 9,
no. 1
pp. 1 – 12
Abstract
Poor adherence to daily antiretrovirals can significantly affect treatment efficacy, but oral long-acting antiretrovirals are currently lacking. Here, the authors develop a once-weekly oral dosage form for anti-HIV drugs, assess its pharmacokinetics in pigs, and model its impact on viral resistance and disease epidemics.
